Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGM

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has shared an update. Zhaoke Ophthalmology Limited reported that all resolutions proposed at its annual general meeting held on May 15, 2026 were approved by shareholders by way of poll. Investors granted the board mandates to repurchase up to 10% of issued shares, issue up to 20% additional shares, and extend the issuance mandate by adding repurchased shares, reinforcing the company’s financial flexibility. Shareholders also backed the re-election of directors, authorization for the board to set director remuneration, and the re-appointment of KPMG as auditor, supporting continuity in governance and oversight. In addition, a special resolution to amend and restate the company’s memorandum and articles of association was passed, signalling corporate housekeeping and potential alignment of the company’s structure and governance framework with its evolving strategic and regulatory requirements. More about Zhaoke Ophthalmology Ltd. Zhaoke Ophthalmology Limited is a Hong Kong-listed ophthalmic pharmaceutical company focused on developing and commercializing treatments for eye diseases. The company operates in the healthcare and life sciences sector, with a market focus on ophthalmology therapies and related medical solutions in Greater China and potentially broader Asian markets. Average Trading Volume: 502,297 Technical Sentiment Signal: Sell Current Market Cap: HK$1.5B